---
title: "CMPX.US (CMPX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CMPX.US/news.md"
symbol: "CMPX.US"
name: "CMPX.US"
parent: "https://longbridge.com/en/quote/CMPX.US.md"
datetime: "2026-05-20T12:31:17.823Z"
locales:
  - [en](https://longbridge.com/en/quote/CMPX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CMPX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CMPX.US/news.md)
---

# CMPX.US (CMPX.US) — Related News

### [Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained](https://longbridge.com/en/news/285256239.md)
*2026-05-05T19:55:33.000Z*
> Analyst Charles Zhu from LifeSci Capital has reiterated a Buy rating on Compass Therapeutics, maintaining a price target

### [Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary](https://longbridge.com/en/news/285204108.md)
*2026-05-05T12:11:01.000Z*
> Compass Therapeutics, Inc. reported its 1Q 2026 results, showing a revenue of $18.76M and a net loss of $18.32M, reflect

### [Compass Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285201846.md)
*2026-05-05T12:02:48.000Z*
### [U.S. stock market update: Compass Therapeutics down 9.51%, concerns in the market triggered by failed cancer trials and target price downgrade](https://longbridge.com/en/news/284629242.md)
*2026-04-29T19:08:05.000Z*
> Compass Therapeutics fell 9.51%; KalVista Pharmaceuticals rose 38.75%, with a transaction volume of USD 1.509 billion; A

### [Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month Low  - What's Next?](https://longbridge.com/en/news/284286691.md)
*2026-04-28T00:49:21.000Z*
> Compass Therapeutics (NASDAQ:CMPX) shares hit a new 52-week low of $1.61, closing at $1.79 with significant trading volu

### [12 Health Care Stocks Moving In Monday's Intraday Session](https://longbridge.com/en/news/284252436.md)
*2026-04-27T17:05:46.000Z*
> On Monday, several health care stocks experienced significant movements. Gainers included Sagimet Biosciences (SGMT) wit

### [Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged](https://longbridge.com/en/news/284246322.md)
*2026-04-27T15:55:37.000Z*
> H.C. Wainwright analyst Joseph Pantginis has reiterated a Buy rating on CMPX stock, maintaining a $24 price target. He c

### [Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients](https://longbridge.com/en/news/284246691.md)
*2026-04-27T15:44:31.000Z*
> Compass Therapeutics Inc. (NASDAQ:CMPX) shares plummeted 60% after the company reported that its drug tovecimig did not